secretin - Profile

What are the generic drug sources for secretin and what is the scope of patent protection?

Secretin is the generic ingredient in three branded drugs marketed by Ferring and Chirhoclin, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for secretin

US Patents:	0
Tradenames:	3
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for secretin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring	SECRETIN-FERRING	secretin	INJECTABLE;INJECTION	018290-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-001	Apr 9, 2004		RX	Yes	Yes
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-002	Jun 21, 2007		RX	Yes	No

Secretin: Investment Scenario and Fundamentals Analysis

Last updated: May 1, 2026

What is secretin, and where does it sit in the drug landscape?

Secretin is a peptide hormone used as an injectable therapeutic product in defined diagnostic contexts rather than as a broad chronic-care medicine. It is the active ingredient in marketed secretin products for gastrointestinal and pancreatic function assessment. In investment terms, secretin’s market profile is shaped by (1) narrow indications, (2) dependence on diagnostic practice patterns, and (3) regulatory and supply-chain constraints typical for peptide injectables.

Clinical use positioning (high level)

• Diagnostic use in gastrointestinal physiology and pancreatic-related assessment pathways.
• Administered as an injectable peptide hormone product.

Economic implication

• Revenue pools track diagnostic volumes and guideline adherence.
• There is limited room for typical “blockbuster expansion” economics because the indication set is constrained and does not scale like chronic therapeutics.

What are the core fundamentals that drive secretin demand?

Secretin fundamentals reduce to a small set of drivers that map directly to purchasing behavior and reimbursement.

1) Indication-driven volume

• Diagnostic testing volume (hospital and specialty clinic throughput).
• Utilization of secretin-based protocols in practice relative to alternatives.

2) Product availability and supply reliability

• Peptide injectables are sensitive to manufacturing scale-up, stability, and batch consistency.
• Stockouts or quality events can cause immediate substitution within diagnostic protocols, often permanently if workflows change.

3) Competitive set and substitution risk

• Secretin competes at the level of “available diagnostic agent” rather than long-term therapeutic differentiation.
• If a facility switches to an alternative protocol or agent, reversion can be slow because protocols embed into ordering systems and staffing practice.

4) Regulatory status and market access

• Label scope and approved use determine reimbursement eligibility.
• Ingredient-specific compendial or guideline alignment influences adoption.

How does IP and patent structure typically impact secretin economics?

Secretin is an older peptide hormone; in most jurisdictions, the original composition-of-matter and early manufacturing-related protections are likely expired or near expiry. For investors, that shifts attention to:

• Product-specific approvals and label exclusivity (where applicable).
• Process improvements that reduce cost of goods and improve manufacturability.
• Manufacturing reliability as a competitive moat in a commodity-like landscape.

Practical consequence

• Pricing and margin structure tends to become competitive as additional suppliers enter, especially if the molecule has limited formulation differentiation.

What does the investment scenario look like under a commercialization lens?

An investment in secretin is best framed as a value capture bet on distribution, supply execution, and reimbursement stability rather than a pipeline bet driven by trial innovation.

Likely opportunity shapes

• Supplier consolidation: investors can capture value when reliable supply is limited and demand is steady.
• Cost-down manufacturing: peptide process optimization can widen gross margin if market pricing stays flat or declines slower than costs.
• Market-access re-entry: if a product is reintroduced after supply disruptions, it can regain share when continuity matters to diagnostic services.

Likely risk shapes

• Protocol substitution: if diagnostic pathways shift away from secretin-based testing, demand falls without needing a new competitor.
• Generic and multi-source pressure: if multiple suppliers compete, pricing compresses.
• Quality and compliance: any recall or manufacturing suspension can take months to restore confidence, and can lead to permanent workflow changes.

Where are the “fundamental” demand risks and tailwinds?

Tailwinds

• Stable hospital diagnostic activity in GI and related specialties.
• Continued use of secretin in protocols where it remains guideline-consistent.
• Tendering and supply contracts that reward reliability.

Risks

• Changes in diagnostic standards of care that reduce secretin usage.
• Supply bottlenecks from peptide manufacturing constraints.
• Margin compression from competition or accelerated entry by additional suppliers.

What are the key operational KPIs that decide whether a secretin investment works?

For an injectable peptide hormone with diagnostic demand, the most decision-relevant metrics are operational and commercial execution KPIs:

• On-time delivery rate by facility and geography.
• Fill-rate under contracted demand during peaks (diagnostic scheduling cycles).
• Batch yield and deviation rate (quality events reduce usable inventory).
• Gross margin per unit net of rebates and tender discounts.
• Share stability: whether the product retains utilization after supply events.

How do pricing and reimbursement dynamics typically behave for diagnostic injectables?

Secretin’s pricing and reimbursement profile tends to be:

• Contract-driven in hospital settings.
• Subject to periodic price pressure when additional sourcing options exist.
• Sensitive to tender cycles and product availability.

For investors, the “valuation lever” is not only price level but also throughput and inventory turns:

• High reliability supports higher ordering frequency.
• Lower stockouts reduce channel friction and lost utilization.

What is the market strategy playbook for investors in secretin?

The strategy should be aligned with the molecule’s diagnostic role.

Commercial strategy

• Focus on hospital purchasing channels and specialty GI/Pancreas service lines.
• Build tender readiness: supply continuity, documentation, and lead-time guarantees.
• Track utilization share in diagnostic pathways rather than broad “market growth.”

Manufacturing strategy

• Maintain peptide stability and consistent potency across batches.
• Invest in deviation reduction and cycle-time improvement to control cost of goods.
• Ensure regulatory readiness for batch release and quality system audits.

Portfolio strategy

• Treat secretin as a cash-generation or risk-mitigating asset within a specialty or injectable portfolio.
• Pair with complementary injectable assets if the investor goal is to smooth demand variability.

What would a credible valuation framing look like for secretin?

For older, indication-limited peptide injectables, valuation typically rests on:

• Sustainable net revenue under competitive pressure.
• Margin resilience driven by manufacturing scale and yield.
• Risk-adjusted probability of continued supply availability and label stability.

A defensible underwriting approach usually prices:

• Demand continuity based on diagnostic volume trends.
• Competitive intensity as multi-source entry increases discounting.
• Supply durability through quality metrics and manufacturing robustness.

Because secretin is not a late-stage pipeline asset, the valuation sensitivity is often highest to operational execution and market-access stability.

Key Takeaways

• Secretin is an injectable peptide hormone with demand driven by diagnostic practice patterns, not chronic treatment expansion.
• Investment fundamentals hinge on supply reliability, label and reimbursement stability, and protocol substitution risk.
• IP value is typically reduced relative to newer drugs; operational and commercial execution are the primary economics drivers.
• The key KPIs are on-time delivery, batch quality metrics, gross margin resilience, and share stability through tender cycles.
• The strongest investment thesis is continuity of supply and controlled cost of goods in a competitive, contract-driven market.

FAQs

1) Is secretin primarily a therapeutic drug or a diagnostic product?

Secretin is used in defined diagnostic contexts as an injectable peptide hormone rather than as a broadly chronic therapeutic.

2) What is the main driver of secretin revenue?

Revenue is driven by diagnostic test utilization in GI and related clinical workflows and the ability to maintain reliable product availability.

3) What operational risks matter most for a secretin investment?

Batch quality stability, manufacturing deviations, and on-time delivery performance matter because diagnostic customers rapidly shift workflows during supply disruptions.

4) How does competition typically affect secretin pricing?

In a multi-source or tender environment, pricing pressure can accelerate and margin can compress unless manufacturing cost and supply continuity outperform.

5) Where does IP typically matter for secretin investors?

For an older peptide hormone, IP impact is usually smaller than for novel therapeutics; economics depend more on product-specific approvals, process execution, and supply reliability.

References

[1] FDA. (n.d.). Drug Trials Snapshots: Secretin. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] World Health Organization. (n.d.). WHO Model List of Essential Medicines. World Health Organization. https://www.who.int/
[3] EMA. (n.d.). European public assessment reports (EPARs) for secretin-containing products. European Medicines Agency. https://www.ema.europa.eu/